CHAPTER 4: MACULAR EDEMA AND MACULAR DEGENERATION MARKET,
4.1. Overview
4.1.1. Market size and forecast, by treatment type
4.2. Drug Therapy
4.2.1. Key trends and growth opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. Laser Treatment
4.3.1. Key trends and growth opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
CHAPTER 5: MACULAR EDEMA AND MACULAR DEGENERATIONMARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Macular Edema
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.2.2.1. Diabetic Macular Edema (DME)
5.2.2.2. Cystoid Macular Edema (CME)
5.3. Macular Degeneration
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.3.2.1. Dry age-related macular degeneration
5.3.2.2. Wet age-related macular degeneration
CHAPTER 6: MACULAR EDEMA AND MACULAR DEGENERATIONMARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals
6.2.1. Market size and forecast
6.2.2. Market analysis, by country
6.3. Clinics
6.3.1. Market size and forecast
6.3.2. Market analysis, by country
6.4. Others
6.4.1. Market size and forecast
6.4.2. Market analysis, by country
CHAPTER 7: MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast, by region
7.2. North America
7.2.1. Key trends and growth opportunities
7.2.2. Market size and forecast, by Treatment
7.2.3. Market size and forecast, by application
7.2.4. Market size and forecast, by end user
7.2.5. Market size and forecast, by country
7.2.5.1. U. S.
7.2.5.2. U. S. market size and forecast, by Treatment
7.2.5.3. U. S. market size and forecast, by application
7.2.5.4. U. S. market size and forecast, by end user
7.2.5.5. Canada
7.2.5.6. Canada market size and forecast, by Treatment
7.2.5.7. Canada market size and forecast, by application
7.2.5.8. Canada market size and forecast, by end user
7.2.5.9. Mexico
7.2.5.10. Mexico market size and forecast, by Treatment
7.2.5.11. Mexico market size and forecast, by application
7.2.5.12. Mexico market size and forecast, by end user
7.3. Europe
7.3.1. Key trends and growth opportunities
7.3.2. Market size and forecast, by Treatment
7.3.3. Market size and forecast, by application
7.3.4. Market size and forecast, by end user
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.2. Germany market size and forecast, by Treatment
7.3.5.3. Germany market size and forecast, by application
7.3.5.4. Germany market size and forecast, by end user
7.3.5.5. France
7.3.5.6. France market size and forecast, by Treatment
7.3.5.7. France market size and forecast, by application
7.3.5.8. France market size and forecast, by end user
7.3.5.9. UK
7.3.5.10. UK market size and forecast, by Treatment
7.3.5.11. UK market size and forecast, by application
7.3.5.12. UK market size and forecast, by end user
7.3.5.13. Italy
7.3.5.14. Italy market size and forecast, by Treatment
7.3.5.15. Italy market size and forecast, by application
7.3.5.16. Italy market size and forecast, by end user
7.3.5.17. Spain
7.3.5.18. Spain market size and forecast, by Treatment
7.3.5.19. Spain market size and forecast, by application
7.3.5.20. Spain market size and forecast, by end user
7.3.5.21. Rest of Europe
7.3.5.22. Rest of Europe market size and forecast, by Treatment
7.3.5.23. Rest of Europe market size and forecast, by application
7.3.5.24. Rest of Europe market size and forecast, by end user
7.4. Asia-Pacific
7.4.1. Key trends and growth opportunities
7.4.2. Market size and forecast, by Treatment
7.4.3. Market size and forecast, by application
7.4.4. Market size and forecast, by end user
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.2. Japan market size and forecast, by Treatment
7.4.5.3. Japan market size and forecast, by application
7.4.5.4. Japan market size and forecast, by end user
7.4.5.5. China
7.4.5.6. China market size and forecast, by Treatment
7.4.5.7. China market size and forecast, by application
7.4.5.8. China market size and forecast, by end user
7.4.5.9. India
7.4.5.10. India market size and forecast, by Treatment
7.4.5.11. India market size and forecast, by application
7.4.5.12. India market size and forecast, by end user
7.4.5.13. Australia
7.4.5.14. Australia market size and forecast, by Treatment
7.4.5.15. Australia market size and forecast, by application
7.4.5.16. Australia market size and forecast, by end user
7.4.5.17. South Korea
7.4.5.18. South Korea market size and forecast, by Treatment
7.4.5.19. South Korea market size and forecast, by application
7.4.5.20. South Korea market size and forecast, by end user
7.4.5.21. Rest of Asia-Pacific
7.4.5.22. Rest of Asia-Pacific market size and forecast, by Treatment
7.4.5.23. Rest of Asia-Pacific market size and forecast, by application
7.4.5.24. Rest of Asia-Pacific market size and forecast, by end user
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Treatment
7.5.3. Market size and forecast, by application
7.5.4. Market size and forecast, by end user
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.2. Brazil market size and forecast, by Treatment
7.5.5.3. Brazil market size and forecast, by application
7.5.5.4. Brazil market size and forecast, by end user
7.5.5.5. Saudi Arabia
7.5.5.6. Saudi Arabia market size and forecast, by Treatment
7.5.5.7. Saudi Arabia market size and forecast, by application
7.5.5.8. Saudi Arabia market size and forecast, by end user
7.5.5.9. South Africa
7.5.5.10. South Africa market size and forecast, by Treatment
7.5.5.11. South Africa market size and forecast, by application
7.5.5.12. South Africa market size and forecast, by end user
7.5.5.13. Rest of LAMEA
7.5.5.14. Rest of LAMEA market size and forecast, by Treatment
7.5.5.15. Rest of LAMEA market size and forecast, by application
7.5.5.16. Rest of LAMEA market size and forecast, by end user
List of Tables
TABLE 01. MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT TYPE, 2020-2030($MILLION)
TABLE 02. MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR DRUG THERAPY, BY REGION, 2020-2030($MILLION)
TABLE 03. MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR LASER TREATMENT, BY REGION, 2020-2030 ($MILLION)
TABLE 04. MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 05. MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR MACULAR EDEMA, BY REGION, 2020-2030 ($MILLION)
TABLE 06. MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR MACULAR DEGENERATION, BY REGION, 2020-2030 ($MILLION)
TABLE 07. MACULAR EDEMA AND MACULAR DEGENERATIONMARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 08. MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR HOSPITALS, BY REGION, 2020-2030 ($MILLION)
TABLE 09. MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR CLINICS, BY REGION, 2020-2030 ($MILLION)
TABLE 10. MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
TABLE 11. MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 12. NORTH AMERICA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 13. NORTH AMERICA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 14. NORTH AMERICA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 15. NORTH AMERICA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 16. U.S. MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 17. U.S. MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 18. U.S. MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 19. CANADA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 20. CANADA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 21. CANADA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 22. MEXICO MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 23. MEXICO MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 24. MEXICO MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 25. EUROPE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 26. EUROPE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 27. EUROPE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 28. EUROPE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 29. GERMANY MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 30. GERMANY MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 31. GERMANY MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 32. FRANCE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 33. FRANCE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 34. FRANCE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 35. UK MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 36. UK MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 37. UK MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 38. ITALY MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 39. ITALY MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 40. ITALY MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 41. SPAIN MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 42. SPAIN MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 43. SPAIN MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 44. REST OF EUROPE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 45. REST OF EUROPE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 46. REST OF EUROPE MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 47. ASIA-PACIFIC MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 48. ASIA-PACIFIC MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 49. ASIA-PACIFIC MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 50. ASIA-PACIFIC MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 51. JAPAN MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 52. JAPAN MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 53. JAPAN MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 54. CHINA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 55. CHINA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 56. CHINA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 57. INDIA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 58. INDIA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 59. INDIA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 60. AUSTRALIA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 61. AUSTRALIA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 62. AUSTRALIA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 63. SOUTH KOREA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 64. SOUTH KOREA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 65. SOUTH KOREA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 66. REST OF ASIA-PACIFIC MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 67. REST OF ASIA-PACIFIC MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 69. LAMEA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 70. LAMEA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 71. LAMEA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 72. LAMEA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 73. BRAZIL MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 74. BRAZIL MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 75. BRAZIL MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 76. SAUDI ARABIA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 77. SAUDI ARABIA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 78. SAUDI ARABIA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 79. SOUTH AFRICA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 80. SOUTH AFRICA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 81. SOUTH AFRICA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 82. REST OF LAMEA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY TREATMENT, 2020-2030 ($MILLION)
TABLE 83. REST OF LAMEA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 84. REST OF LAMEA MACULAR EDEMA AND MACULAR DEGENERATION MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 85. ALIMERA SCIENCES: COMPANY SNAPSHOT
TABLE 86. ALIMERA SCIENCES: OPERATING SEGMENTS
TABLE 87. ALIMERA SCIENCES: PRODUCT PORTFOLIO
TABLE 88. ALIMERA SCIENCES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 89. ABBVIE: COMPANY SNAPSHOT
TABLE 90. ABBVIE: OPERATING SEGMENTS
TABLE 91. ABBVIE: PRODUCT PORTFOLIO
TABLE 92. ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 93. BAUSCH HEALTH: COMPANY SNAPSHOT
TABLE 94. BAUSCH HEALTH: OPERATING SEGMENTS
TABLE 95. BASUCH HEALTH: PRODUCT PORTFOLIO
TABLE 96. BAUSCH HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 97. BAYER: COMPANY SNAPSHOT
TABLE 98. BAYER: OPERATING SEGMENTS
TABLE 99. BAYER: PRODUCT PORTFOLIO
TABLE 100. BAYER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 101. ROCHE: COMPANY SNAPSHOT
TABLE 102. ROCHE: OPERATING SEGMENTS
TABLE 103. ROCHE: PRODUCT PORTFOLIO
TABLE 104. ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 105. GSK : PRODUCT PORTFOLIO
TABLE 106. GSK: OPERATING SEGMENTS
TABLE 107. GSK : PRODUCT PORTFOLIO
TABLE 108. KUBOTA: COMPANY SNAPSHOT
TABLE 109. KUBOTA: OPERATING SEGMENTS
TABLE 110. KUBOTA: PRODUCT PORTFOLIO
TABLE 111. KUBOTA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 112. NOVARTIS : OPERATING SEGMENTS
TABLE 113. NOVARTIS : PRODUCT PROTFOLIO
TABLE 114. NOVARTIS: KEY STRAGIC MOVES AND DEVELOPMENTS
TABLE 115. REGENERON: COMPANY SNAPSHOT
TABLE 116. REGENERON: OPERATING SEGMENTS
TABLE 117. REGENERON: PRODUCT PORTFOLIO
TABLE 118. REGENERON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 119. REGEN X BIO: COMPANY SNAPSHOT
TABLE 120. REGEN X BIO: PRODUCT PORTFOLIO
TABLE 121. REGEN X BIO : KEY STRATEGIC MOVES AND DEVELOPMENTS
List of Figures
FIGURE 01. TOP INVESTMENT POCKETS
FIGURE 02. HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 03. MODERATE BARGAINING POWER OF BUYERS
FIGURE 04. MODERATE THREAT OF SUBSTITUTES
FIGURE 05. MODERATE THREAT OF NEW ENTRANTS
FIGURE 06. HIGH INTENSITY OF RIVALRY
FIGURE 07. TOP PLAYER POSITIONING, 2020
FIGURE 08. COMPARATIVE SHARE ANALYSIS OF MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR DRUG THERAPY BY COUNTRY, 2020 & 2030 (%)
FIGURE 09. COMPARATIVE SHARE ANALYSIS OF MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR LASER TREATMENT BY COUNTRY, 2020 & 2030 (%)
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR MACULAR EDEMA BY COUNTRY, 2020 & 2030 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR MACULAR DEGENERATION BY COUNTRY, 2020 & 2030 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR HOSPITALS BY COUNTRY, 2020 & 2030 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR CLINICS BY COUNTRY, 2020 & 2030 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF MACULAR EDEMA AND MACULAR DEGENERATION MARKET FOR OTHERS BY COUNTRY, 2020 & 2030 (%)
FIGURE 15. ALIMERA SCIENCES: NET SALES, 2018-2020 ($MILLION)
FIGURE 16. ALIMERA SCIENCES:REVENUE SHARE BY REGION, 2020 (%)
FIGURE 17. ABBVIE: NET SALES 2020 (%)
FIGURE 18. ABBVIE: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 19. BAUSCH HEALTH: NET SALES, 2018-2020 ($MILLION)
FIGURE 20. BAUSCH HEALTH: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 21. BAUSCH HEALTH: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 22. BAYER: NET SALES, 2018-2020 ($MILLION)
FIGURE 23. BAYER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 24. BAYER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 25. ROCHE: NET SALES, 2018-2020 ($MILLION)
FIGURE 26. ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 27. ROCHE: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 28. GSK: NET SALES, 2018-2020 ($MILLION)
FIGURE 29. GSK: REVENUE SHARE BY SEGMENT, 2018-2020 ($MILLION)
FIGURE 30. GSK: REVENUE SHARE BY REGION, 2018-2020 ($MILLION)
FIGURE 31. NOVARTIS: NET SALES, 2018-2020 ($MILLION)
FIGURE 32. NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 33. NOVARTIS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 34. REGENERON: NET SALES, 2018-2020 ($MILLION)
FIGURE 35. REGENERON: REVENUE SHARE BY SEGMENT, 2020 (%)